Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2003

View Archived Issues

Licofelone downregulates PMN/platelet function in vitro

Single-agent epratuzumab trial closes

RG-2133 enters phase I/II for bipolar disorder and major depression

Pharmacia claims new alpha7 nicotinic agonists for schizophrenia and cognitive dysfunction

AIDS vaccine developed at Emory and NIH enters clinical testing

Celera Genomics and Aventis jointly develop novel cathepsin S inhibitors

New integrin antagonists with utility in asthma covered by Aventis patent

Roche scientists prepare and test new 5-HT6 agonists

Lilly claims antitumor benzoylsulfonamides and sulfonylbenzamidines

Nippon Soda reports novel cGMP-PDE inhibitors with potential as vasodilators

Sato patent covers antibacterial quinolizinones

FR-167653 as a potential new therapy for endotoxemia

Further evidence supporting PARP inhibition as a therapeutic target in circulatory shock

Clinical testing of new PPARgamma agonist from Tularik commences

Rights to cantuzumab mertansine returned to ImmunoGen

HuMax-CD4 enters phase II clinical studies for CTCL

Clearance received in U.S. for efficacy trials of Helivax

Ketek deemed approvable by the FDA for respiratory tract infections

Abbott begins supplying Humira to pharmacies within a week of approval

Nastech reacquires rights to intranasal product for sexual dysfunction

BMS-207940: a second-generation ETA receptor antagonist with a favorable pharmacokinetic profile

CB1 receptor-mediated discriminative stimulus effects of Bay-38-7271

Naltrexone well tolerated and effective in pruritus caused by cholestasis

New data on once-daily lonafarnib in patients with advanced solid tumors

Improved bone mineral density found for teriparatide in male patients with osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...